Drugs / BD114VLP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07170254 | Sep 2025 → Dec 2026 expected | cervical intraepithelial neoplasia grade 2/3 | Shanghai BDgene Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BD114VLP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07170254 ↗ |
| Known as | BD114 | “CRISPR/Cas9 instantaneous gene editing therapy, called BD114VLP (also BD114) which is a developing product of gene therapy from modified third-generation integrated defective...” NCT07170254 ↗ |
| Action | Inhibit | “It works to knock out or knock down HPV-16 E6/E7 genes integrated in HSIL cell genome” NCT07170254 ↗ |
| Modality | CRISPR / gene editing | “CRISPR/Cas9 instantaneous gene editing therapy” NCT07170254 ↗ |
| Route | Other | “A single dosing BD114 injection by topical intraepithelial injection of HSIL lesion.” NCT07170254 ↗ |
| Route | Topical | “A single dosing BD114 injection by topical intraepithelial injection of HSIL lesion.” NCT07170254 ↗ |